FDA Approves Upadacitinib for Non-Radiographic Axial Spondyloarthritis in patients with objective signs of inflammation who have had an inadequate response or intolerance to tumor necrosis factor (TNF) blocker therapy.
https://bit.ly/3swAPZr
